GAITHERSBURG, Md., Sept. 25 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that Herren Wu, Ph.D., senior director and head
of antibody discovery and protein engineering, received the Senior Technology
Fellow Emerald Honors award from Science Spectrum magazine at the 2006 Annual
Minorities in Research Science (MIRS) Awards Conference that took place
September 14-16, 2006 in Baltimore, Maryland.
The MIRS conference examines and celebrates the outstanding achievements
of men and women from multicultural communities who are working in science.
The Senior Technology Fellow award recognizes a professional working in
research and development who translates basic science discoveries into
inventions. A pioneer of innovative antibody discovery and engineering
technologies, Dr. Wu leads MedImmune's drug discovery efforts in the
development of several pipeline products in the oncology, inflammatory disease
and infectious disease arenas. Dr. Wu is credited with building a multi-
disciplinary department that plays a vital role within the organization.
"We congratulate Dr. Wu, who is recognized among his peers as both an
exceptional scientist and highly effective leader, on this important
achievement," said Peter Kiener, D. Phil, senior vice president, research.
"Dr. Wu sets an outstanding example of dedication and integrity, while
maintaining a strong focus on collaboration and the professional development
of his staff. It is our hope that more young minority scientists choose to
follow Dr. Wu's example and to employ their talents to help further scientific
advances."
Dr. Wu, named as co-inventor on five patents and nearly 20 patent
applications, joined MedImmune in January 2002. Prior to joining MedImmune, he
served as associate director, head, molecular biology at Tanox, Inc. from 2000
to 2002. Before joining Tanox, he held a variety of increasingly responsible
research positions, culminating as associate director of antibody engineering
and discovery, at Applied Molecular Evolution, a subsidiary of Eli Lilly & Co,
between 1995 and 2000. Dr. Wu received his bachelor's degree in chemistry from
the National Taiwan University and his doctorate in molecular and cellular
biology from the University of Massachusetts, Amherst. He completed his
postdoctoral training at The Scripps Research Institute in La Jolla,
California.
As a company proud of its diversity and committed to attracting and
retaining world-class talent, MedImmune was the exclusive sponsor of the High
School Program within the MIRS conference. Sponsored by Science Spectrum, a
career development magazine focused on reaching multicultural communities, the
conference celebrates the superior achievements of Blacks, Hispanics, Asian
Americans and Native Americans in science and also honors those who support
them in their careers. The conference offers a forum for discussion of career
issues common to minorities in science, and provides the opportunity for
minority students to meet with companies committed to diversity and learn
about the rewards of a career in research science.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,400 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
CONTACT: Media: Kate Barrett, +1-301-398-4320, Investors: Peter Vozzo,
+1-301-398-4358, both of MedImmune, Inc.